Skip to main content
SpringerLink
Log in

Cognitive Function in Breast Cancer Survivors

  • Chapter
  • First Online:
Book cover Adjuvant Therapy for Breast Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 151))

Cancer survivors have coined the terms “chemobrain” and “chemofog” to refer to the problems that patients experience with their memory and/or concentration during and after completing chemotherapy. A number of studies have confirmed that some breast cancer survivors suffer cognitive impairment after chemotherapy [1–8], although recent studies have found that some women’s cognitive impairment may predate the chemotherapy [9], and hormonal treatment may also impact on cognitive function [8, 10]. For most women the problem appears subtle and often improves after ceasing chemotherapy; however, for a subset of survivors, the symptoms are sustained and can impact significantly on their quality of life and ability to function in their everyday activities [7, 11, 12].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–701.

    PubMed  CAS  Google Scholar 

  2. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93.

    Article  PubMed  CAS  Google Scholar 

  3. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8.

    Article  PubMed  Google Scholar 

  4. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–50.

    Article  PubMed  CAS  Google Scholar 

  5. Wieneke MH, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61–6.

    Article  Google Scholar 

  6. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;21:4175–83.

    Article  PubMed  Google Scholar 

  7. Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: Report of a Workshop. J Clin Oncol. 2004;22:2233–9.

    Article  PubMed  Google Scholar 

  8. Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.

    Article  PubMed  Google Scholar 

  9. Wefel JS, Lenzi R, Theriault R, et al. 'Chemobrain' in breast carcinoma?: A prologue. Cancer. 2004;101:466–75.

    Article  PubMed  Google Scholar 

  10. Shilling V, Jenkins V, Fallowfield L, et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Mol Biol. 2003;86:405–12.

    Article  PubMed  CAS  Google Scholar 

  11. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2000;19:812–20.

    Article  Google Scholar 

  12. Downie FP, Mar Fan HG, Houede-Tchen N, et al. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: Evaluation with patient interview after formal assessment. Psychooncology. 2006;15:921–30.

    Google Scholar 

  13. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: What are the tools? Clin Breast Cancer. 2002; 3(Suppl 3):S91–9.

    Article  PubMed  Google Scholar 

  14. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234–48.

    Article  PubMed  Google Scholar 

  15. Butters N, Grant I, Haxby J, et al. Assessment of AIDS-related cognitive changes: Recommendations of the NIMH Workshop on Neuropsychological Assessment Approaches. J Clin Exp Neuropsychol. 1990;12:963–78.

    Article  PubMed  CAS  Google Scholar 

  16. Cummings JL, Benson DF. Subcortical dementia. Review of an emerging concept. Arch Neurol. 1984;41:874–9.

    Article  PubMed  CAS  Google Scholar 

  17. Massman PJ, Delis DC, Butters N, et al. Are all subcortical dementias alike? Verbal learning and memory in Parkinson's and Huntington's disease patients. J Clin Exp Neuropsychol. 1990;12:729–44.

    Article  PubMed  CAS  Google Scholar 

  18. Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41:685–91.

    PubMed  CAS  Google Scholar 

  19. Heaton RK, Kirson D, Velin D, RA. Grant I. and the HNRC Group: The Utility of Clinical Ratings for Detecting Cognitive Change in HIV Infection, in Grant IM, A. (ed) Neuropsychology of HIV Infection. New York: Oxford University Press, 1994, pp.188–206.

    Google Scholar 

  20. Heaton RK, Grant I, Butters N, et al. The HNRC 500–neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:231–51

    Article  PubMed  CAS  Google Scholar 

  21. Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26:307–19.

    Article  PubMed  Google Scholar 

  22. Martin EM, Sullivan TS, Reed RA, et al. Auditory working memory in HIV-1 infection. J Int Neuropsychol Soc. 2001;7:20–6.

    Article  PubMed  CAS  Google Scholar 

  23. Durvasula RS, Miller EN, Myers HF, et al. Predictors of neuropsychological performance in HIV positive women. J Clin Exp Neuropsychol. 2001;23:149–63.

    Article  PubMed  CAS  Google Scholar 

  24. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. 3rd ed. New York: The Psychological Corporation; 1997

    Google Scholar 

  25. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3:215–22.

    Article  PubMed  Google Scholar 

  26. Minisini A, Atalay G, Bottomley A, et al. What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol. 2004;5:273–82.

    Article  PubMed  Google Scholar 

  27. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (second of two parts). N Engl J Med. 1974;291:127–33

    Article  PubMed  CAS  Google Scholar 

  28. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med. 1974;291:75–81.

    Article  PubMed  CAS  Google Scholar 

  29. Oxman TE, Silberfarb PM. Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry. 1980;137:1263–5.

    PubMed  CAS  Google Scholar 

  30. Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry. 1980;137:597–601.

    PubMed  CAS  Google Scholar 

  31. Kaasa S, Olsnes BT, Thorud E, et al. Reduced short-term neuropsychological performance in patients with nonsmall-cell lung cancer treated with cisplatin and etoposide. Antibiot Chemother. 1988;41:226–31.

    PubMed  CAS  Google Scholar 

  32. Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: Effect of previous treatment. Neurology. 1992;42:434–6.

    PubMed  CAS  Google Scholar 

  33. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer. 1995;12:231–5.

    Article  PubMed  CAS  Google Scholar 

  34. Silberfarb PM. Chemotherapy and cognitive defects in cancer patients. Annu Rev Med. 1983;34:35–46.

    Article  PubMed  CAS  Google Scholar 

  35. Komaki R, Meyers CA, Shin DM, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys. 1995;33:179–82.

    Article  PubMed  CAS  Google Scholar 

  36. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst. 2003;95:190–7.

    Article  PubMed  CAS  Google Scholar 

  37. Bender CM, Sereika SM, Berga SL, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15:422–30.

    Google Scholar 

  38. Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507.

    Article  PubMed  Google Scholar 

  39. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006.

    Google Scholar 

  40. Mar Fan H, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock I.F. Fatigue, menopausal symptoms and cognitive function in women following adjuvant chemotherapy for breast cancer: One and two year follow-up of a prospective controlled study. J Clin Oncol. 2005;23:8025–32.

    Article  Google Scholar 

  41. O'Shaughnessy JA, Vukelja SJ, Holmes FA, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer. 2005;5:439–46.

    Article  PubMed  Google Scholar 

  42. Schagen SB, Muller MJ, Boogerd W, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387–97.

    Article  PubMed  CAS  Google Scholar 

  43. Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: Evaluation of long-term treatment effects. Ann Oncol. 2006;17:415–23.

    Article  PubMed  CAS  Google Scholar 

  44. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9.

    Article  PubMed  CAS  Google Scholar 

  45. Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect? J Natl Cancer Inst. 1998;90:182–3.

    Article  PubMed  CAS  Google Scholar 

  46. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3(Suppl 3):S84–90.

    Article  PubMed  CAS  Google Scholar 

  47. Bender CM, Paraska KK, Sereika SM, et al. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: A critical review. J Pain Symptom Manage. 2001;21:407–24.

    Article  PubMed  CAS  Google Scholar 

  48. Cimprich B. Symptom management: Loss of concentration. Semin Oncol Nurs. 1995;11:279–88.

    Article  PubMed  CAS  Google Scholar 

  49. McAllister TW, Ahles TA, Saykin AJ, et al. Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments. Curr Psychiatry Rep. 2004;6:364–71.

    Article  PubMed  Google Scholar 

  50. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients: A review of the literature. Psychooncology. 1997;6:169–77.

    Article  PubMed  CAS  Google Scholar 

  51. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park). 2000;14:75–9;discussion 79,81–2,85.

    PubMed  CAS  Google Scholar 

  52. Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park). 1990;4:115–22;discussion 122,126–7,130.

    PubMed  CAS  Google Scholar 

  53. Meyers CA, Weitzner M, Byrne K, et al. Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994;12:820–6.

    PubMed  CAS  Google Scholar 

  54. Meyers CA, Weitzner MA. Neurobehavioral functioning and quality of life in patients treated for cancer of the central nervous system. Curr Opin Oncol. 1995;7:197–200.

    Article  PubMed  CAS  Google Scholar 

  55. Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park). 2001;15:613–8;discussion 618,621–4.

    PubMed  CAS  Google Scholar 

  56. O'Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs. 2003;19:17–24.

    Article  PubMed  Google Scholar 

  57. O'Shaughnessy JA. Chemotherapy-induced cognitive dysfunction: A clearer picture. Clin Breast Cancer. 2003;4(Suppl 2):S89–94.

    Article  PubMed  Google Scholar 

  58. Peterson LG, Popkin MK. Neuropsychiatric effects of chemotherapeutic agents for cancer. Psychosomatics. 1980;21:141–53.

    PubMed  CAS  Google Scholar 

  59. Redd WH, Silberfarb PM, Andersen BL, et al. Physiologic and psychobehavioral research in oncology. Cancer. 1991;67:813–22.

    Article  PubMed  CAS  Google Scholar 

  60. Rugo HS, Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol. 2003;30:749–62.

    Article  PubMed  CAS  Google Scholar 

  61. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry. 2003;8:201–16.

    Article  PubMed  Google Scholar 

  62. Schagen SB, Muller MJ, Boogerd W, et al. Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clin Breast Cancer. 2002;3(Suppl 3):S100–8.

    Article  PubMed  Google Scholar 

  63. Oxman TE, Schnurr PP, Silberfarb PM. Assessment of cognitive function in cancer patients. Hosp J. 1986;2:99–128 .

    Article  PubMed  CAS  Google Scholar 

  64. Silberfarb PM, Oxman TE. The effects of cancer therapies on the central nervous system. Adv Psychosom Med. 1988;18:13–25.

    PubMed  CAS  Google Scholar 

  65. Tope DM, Ahles TA, Silberfarb PM. Psycho-oncology: Psychological well-being as one component of quality of life. Psychother Psychosom. 1993;60:129–47.

    Article  PubMed  CAS  Google Scholar 

  66. Troy L, McFarland K, Littman-Power S, et al. Cisplatin-based therapy: A neurological and neuropsychological review. Psychooncology. 2000;9:29–39.

    Article  PubMed  CAS  Google Scholar 

  67. Morse R, Rodgers J, Verrill M, et al. Neuropsychological functioning following systemic treatment in women treated for breast cancer: A review. Eur J Cancer. 2003;39:2288–97.

    Article  PubMed  CAS  Google Scholar 

  68. Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: the art of the possible. Clin Breast Cancer. 2002;3(Suppl 3):S121–7.

    Article  PubMed  Google Scholar 

  69. Matsuda T, Takayama T, Tashiro M, et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients–evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12:279–87.

    Article  PubMed  Google Scholar 

  70. Raffa RB, Duong PV, Finney J, et al. Is 'chemo-fog'/'chemo-brain' caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31:129–38.

    Article  PubMed  CAS  Google Scholar 

  71. Kayl AE, Wefel JS, Meyers CA. Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther. 2006;13:362–9.

    Article  PubMed  Google Scholar 

  72. Castellon SA, Silverman DH, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat. 2005;92:199–206.

    Article  PubMed  Google Scholar 

  73. Wefel JS, Kayl AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: A conceptual review of an emerging target. Br J Cancer. 2004;90:1691–6.

    PubMed  CAS  Google Scholar 

  74. Baumgartner K. Neurocognitive changes in cancer patients. Semin Oncol Nurs. 2004;20:284–90.

    Article  PubMed  Google Scholar 

  75. Paraska K, Bender CM. Cognitive dysfunction following adjuvant chemotherapy for breast cancer: Two case studies. Oncol Nurs Forum. 2003;30:473–8.

    Article  PubMed  Google Scholar 

  76. Ahles TA. Do systemic cancer treatments affect cognitive function? Lancet Oncol. 2004;5:270–1.

    Article  PubMed  Google Scholar 

  77. Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967–82.

    Article  PubMed  Google Scholar 

  78. Falleti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.

    Article  PubMed  Google Scholar 

  79. Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33.

    Article  PubMed  Google Scholar 

  80. Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76–89.

    Article  PubMed  Google Scholar 

  81. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61–6.

    Article  Google Scholar 

  82. Tchen N JH, Downie F, Yi Q, Hu H, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol. 2003;22(22):4175–83.

    Google Scholar 

  83. Mar Fan H, Vardy J, Xu W, Tannock IF. Does cognitive impairment after chemotherapy improve over time or does practice make perfect? In reply. J Clinl Oncol. 2006;24:5171–2.

    Article  Google Scholar 

  84. Cimprich B, So H, Ronis DL, et al. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14:70–8.

    Article  PubMed  Google Scholar 

  85. Shilling V, Jenkins V, Morris R, et al. The effects of adjuvant chemotherapy on cognition in women with breast cancer–preliminary results of an observational longitudinal study. Breast. 2005;14:142–50.

    Article  PubMed  CAS  Google Scholar 

  86. Symes E, Maruff P, Ajani A, et al. Issues associated with the identification of cognitive change following coronary artery bypass grafting. Aust N Z J Psychiatry. 2000;34:770–84.

    Article  PubMed  CAS  Google Scholar 

  87. Ingraham L, Aiken, CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology. 1996;10:120–4.

    Article  Google Scholar 

  88. Bornstein R. Methodological and conceptual issues in the study of cognitive change in HIV infection, in Grant IM A. ed. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994

    Google Scholar 

  89. Gonzalez R, Heaton RK, Moore DJ, et al. Computerized reaction time battery versus a traditional neuropsychological battery: Detecting HIV-related impairments. J Int Neuropsychol Soc. 2003;9:64–71.

    Article  PubMed  Google Scholar 

  90. Vardy J. Cognitive impairment postchemotherapy. Review. American Journal of Oncology. 2004;3:568–70.

    Google Scholar 

  91. Shilling V, Jenkins V, Trapala IS. The (mis)classification of chemo-fog – methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat. 2005;1–5.

    Google Scholar 

  92. Taylor MJ, Heaton RK. Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc. 2001;7:867–74.

    Article  PubMed  CAS  Google Scholar 

  93. Fletcher RH, Fletcher SW, Wagner EH. Responsiveness, In: Satterfield T ed. Clinical epidemiology: the essentials 2nd ed. Baltimore: Williams & Wilkins; 1988, pp. 71–72.

    Google Scholar 

  94. Reitan RM, Wolfson, D. The Halstead-Reitan Neuropscyhological Test Battery: Theory and Clinical Interpretation 2nd ed. Tucson, Arizona: Neuropsychology Press, 1993.

    Google Scholar 

  95. White DA, Heaton RK, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1:304–15.

    Article  PubMed  CAS  Google Scholar 

  96. Miller EN, Wilkie FL. Computerized Testing to Assess Cognition in HIV-Positive Individuals, In Grant I, Martin A ed. Neuropsychology of HIV Infection. New York: Oxford University Press; 1994, pp. 161–75.

    Google Scholar 

  97. Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol. 2003;21:3557–8.

    Article  PubMed  Google Scholar 

  98. Miller EN, Satz P, Visscher B. Computerized and conventional neuropsychological assessment of HIV-1-infected homosexual men. Neurology. 41:1608–16.

    Google Scholar 

  99. Cull A, Hay C, Love SB, et al. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 1996;74:1674–9.

    Article  PubMed  CAS  Google Scholar 

  100. Servaes P, Verhagen CA, Bleijenberg G. Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer. 2002;95:2017–26.

    Article  PubMed  Google Scholar 

  101. Poppelreuter M, Weis J, Kulz AK, et al. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer. 2004;40:43–9.

    Article  PubMed  CAS  Google Scholar 

  102. Sbordone RJ. Limitations of neuropsychological testing to predict the cognitive and behavioral functioning of persons with brain injury in real-world settings. NeuroRehabilitation. 2001;16:199–201.

    PubMed  CAS  Google Scholar 

  103. Radziwillllowicz W, Radziwillllowicz, P. Subjective and objective assessment of memory functions in endogenous depression. Arch Psych Psychother. 2000;2:33–41.

    Google Scholar 

  104. Vermeulen J, Aldenkamp AP, Alpherts WC. Memory complaints in epilepsy: Correlations with cognitive performance and neuroticism. Epilepsy Res. 1993;15:157–70.

    Article  PubMed  CAS  Google Scholar 

  105. Vercoulen JH, Swanink CM, Galama JM, et al. The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: Development of a model. J Psychosom Res. 1998;45:507–17.

    Article  PubMed  CAS  Google Scholar 

  106. Sunderland A, Watts K, Baddeley AD, et al. Subjective memory assessment and test performance in elderly adults. J Gerontol. 1986;41:376–84.

    PubMed  CAS  Google Scholar 

  107. Millikin CP, Rourke SB, Halman MH, et al. Fatigue in HIV/AIDS is associated with depression and subjective neurocognitive complaints but not neuropsychological functioning. J Clin Exp Neuropsychol. 2003;25:201–15.

    Article  PubMed  Google Scholar 

  108. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317–31.

    Article  PubMed  Google Scholar 

  109. Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11:6–15.

    Google Scholar 

  110. Booth-Jones M, Jacobsen PB, Ransom S, et al. Characteristics and correlates of cognitive functioning following bone marrow transplantation. Bone Marrow Transplant. 2005;36:695–702.

    Article  PubMed  CAS  Google Scholar 

  111. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs. 1999;22:185–94;quiz 195.

    Article  PubMed  CAS  Google Scholar 

  112. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2002;3(Suppl 3):S116–20.

    Article  PubMed  Google Scholar 

  113. Newman T, Browner WS, Hulley SB. Enhancing causal inference in observational studies, Designing clinical research: An epidemiologic approach 2nd ed. Philadelphia, Pa., Lippincott: Williams & Wilkins; 2000, pp. 125–38.

    Google Scholar 

  114. Fletcher R, Fletcher SW, Wagner EH. Cause, in Satterfield T ed. Clinical Epidemiology 3rd ed. Baltimore: Lippincott Williams & Wilkins; 1996, pp. 228–48.

    Google Scholar 

  115. Winocur G, Vardy J, Binns MA, et al. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav. 2006;85:66–75.

    Article  PubMed  CAS  Google Scholar 

  116. Lee GD, Longo DL, Wang Y, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res. 2006;12:198–205.

    Article  PubMed  CAS  Google Scholar 

  117. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer. 2007;109:146–56.

    Article  PubMed  Google Scholar 

  118. Saykin AJ, Ahles TA, Schoenfeld J.D. et al. Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsych Soc. 2003;9:246.

    Google Scholar 

  119. Booth CM, Vardy J, Crawley A, et al. Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. J Clin Oncol (Meeting Abstracts). 2006;24:8501.

    Google Scholar 

  120. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.

    Google Scholar 

  121. Schagen SB, Hamburger HL, Muller MJ, et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51:159–65.

    Article  PubMed  CAS  Google Scholar 

  122. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer. 2006;7:67–78.

    Article  PubMed  CAS  Google Scholar 

  123. Kreukels BP, Schagen SB, Ridderinkhof KR, et al. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2005;94:53–61.

    Article  PubMed  CAS  Google Scholar 

  124. Vezmar S, Becker A, Bode U, et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49:92–104.

    Article  PubMed  CAS  Google Scholar 

  125. Vardy J, Wong K, Yi QL, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14:1111–8.

    Google Scholar 

  126. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntington). 2000;14:151–61.

    PubMed  CAS  Google Scholar 

  127. Cella D, Davis K, Breitbart W, et al. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol. 2001;19:3385–91.

    PubMed  CAS  Google Scholar 

  128. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13:63–74.

    Article  PubMed  CAS  Google Scholar 

  129. Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998;34:1670–6.

    Article  PubMed  CAS  Google Scholar 

  130. Knobf MT. Physical and psychologic distress associated with adjuvant chemotherapy in women with breast cancer. J Clin Oncol. 1986;4:678–84.

    PubMed  CAS  Google Scholar 

  131. Stone P, Richardson A, Ream E, et al. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000;11:971–5,

    Article  PubMed  CAS  Google Scholar 

  132. Stone P, Ream E, Richardson A, et al. Cancer-related fatigue–a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. Eur J Cancer Care (Engl). 2003;12:20–7.

    Article  CAS  Google Scholar 

  133. Ashbury FD, Findlay H, Reynolds B, et al. A Canadian survey of cancer patients' experiences: are their needs being met? J Pain Symptom Manage. 1998;16:298–306.

    Article  PubMed  CAS  Google Scholar 

  134. Stone P. The measurement, causes and effective management of cancer-related fatigue. Int J Palliat Nurs. 2002;8:120–8.

    PubMed  Google Scholar 

  135. Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998;16:1689–96.

    PubMed  CAS  Google Scholar 

  136. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18:743–53

    PubMed  CAS  Google Scholar 

  137. Jacobsen PB, Stein K. Is Fatigue a Long-term Side Effect of Breast Cancer Treatment? Cancer Control. 1999;6:256–63.

    PubMed  Google Scholar 

  138. Richardson A. Fatigue in cancer patients: A review of the literature. Eur J Cancer Care (Engl). 1995;4:20–32.

    Article  CAS  Google Scholar 

  139. Jacobsen PB. Assessment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;93–7.

    Google Scholar 

  140. Massie M. Depression, in Holland J, Rowland ed. Handbook of Psycho-oncology. New York: Oxford University Press; 1990, pp.283–90.

    Google Scholar 

  141. Keating NL, Norredam M, Landrum MB, et al. Physical and mental health status of older long-term cancer survivors. J Am Geriatr Soc. 2005;53:2145–52.

    Article  PubMed  Google Scholar 

  142. Honda K, Goodwin RD. Cancer and mental disorders in a national community sample: Findings from the national comorbidity survey. Psychother Psychosom. 2004;73:235–42.

    Article  PubMed  Google Scholar 

  143. Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: Analyses of the National Health Interview Survey. J Clin Oncol 2002;20:4581–90.

    Article  PubMed  Google Scholar 

  144. Fallowfield L, Ratcliffe D, Jenkins V, et al. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer. 2001;84:1011–15.

    Article  PubMed  CAS  Google Scholar 

  145. Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA. 1983;249:751–7.

    Article  PubMed  CAS  Google Scholar 

  146. Deimling GT, Kahana B, Bowman KF, et al. Cancer survivorship and psychological distress in later life. Psychooncology. 2002;11:479–94.

    Article  PubMed  Google Scholar 

  147. Eberhardt B, Dilger S, Musial F, et al. Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol. 2006;132:234–40.

    Article  PubMed  Google Scholar 

  148. Eberhardt B, Dilger S, Musial F, et al. Medium-term effects of chemotherapy in older cancer patients. Support Care Cancer. 2006;14:216–22.

    Article  PubMed  Google Scholar 

  149. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;351:1451–67.

    Article  Google Scholar 

  150. Eberling JL, Wu C, Tong-Turnbeaugh R, et al. Estrogen- and tamoxifen-associated effects on brain structure and function. Neuroimage. 2004;21:364–71.

    Article  PubMed  Google Scholar 

  151. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592–7.

    Article  PubMed  CAS  Google Scholar 

  152. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006;91:1802–10.

    Article  PubMed  CAS  Google Scholar 

  153. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA. 2004;291:2959–68.

    Article  PubMed  CAS  Google Scholar 

  154. Yaffe K, Lui LY, Grady D, et al. Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000;356:708–12.

    Article  PubMed  CAS  Google Scholar 

  155. Barrett-Connor E, Goodman-Gruen D. Cognitive function and endogenous sex hormones in older women. J Am Geriatr Soc. 1999;47:1289–93.

    PubMed  CAS  Google Scholar 

  156. Ciocca DR, Roig LM. Estrogen receptors in human nontarget tissues: Biological and clinical implications. Endocr Rev. 1995;16:35–62.

    PubMed  CAS  Google Scholar 

  157. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA. 2003;289:2663–72.

    Article  PubMed  CAS  Google Scholar 

  158. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165–76.

    Article  PubMed  CAS  Google Scholar 

  159. Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: A European survey. Ann Oncol. 2005;16:655–63.

    Article  PubMed  CAS  Google Scholar 

  160. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191–214.

    Article  PubMed  CAS  Google Scholar 

  161. Joseph JA, Denisova N, Fisher D, et al. Age-related neurodegeneration and oxidative stress: Putative nutritional intervention. Neurol Clin. 1998;16:747–55.

    Article  PubMed  CAS  Google Scholar 

  162. Fillit HM, Butler RN, O'Connell AW, et al. Achieving and maintaining cognitive vitality with aging. Mayo Clin Proc. 2002;77:681–96.

    Article  PubMed  Google Scholar 

  163. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7:192–201.

    Article  PubMed  CAS  Google Scholar 

  164. Dietrich J, Han R, Yang Y, et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5:22.

    Article  PubMed  Google Scholar 

  165. Madhyastha S, Somayaji SN, Rao MS, et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol. 2002;80:1076–84.

    Article  PubMed  CAS  Google Scholar 

  166. Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003;21:4184–93.

    Article  PubMed  Google Scholar 

  167. Jacobsen PB, Garland LL, Booth-Jones M, et al. Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. J Pain Symptom Manage. 2004;28:7–18.

    Article  PubMed  CAS  Google Scholar 

  168. Mar Fan H, Yi Q-L, Park A, Braganza S, Chang J, Couture F, Tannock IF. The influence of erythropoietin on cognitive function in women following adjuvant chemotherapy for breast cancer. San Antonio Breast Cancer Symposium. San Antonio, Texas, 2004 Abstract No. 3075

    Google Scholar 

  169. Ramassamy C, Averill D, Beffert U, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med. 1999;27:544–53.

    Article  PubMed  CAS  Google Scholar 

  170. Fishel ML, Vasko MR, Kelley MR. DNA repair in neurons: So if they don't divide what's to repair? Mutat Res. 2007;614:24–36.

    Article  PubMed  CAS  Google Scholar 

  171. Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation. 2003;107:I17–21.

    PubMed  Google Scholar 

  172. Falanga A, Levine MN, Consonni R, et al. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost. 1998;79:23–7.

    PubMed  CAS  Google Scholar 

  173. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation. 1998;98:196–9.

    PubMed  CAS  Google Scholar 

  174. Shea TB, Lyons-Weiler J, Rogers E. Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheimers Dis. 2002;4:261–7.

    PubMed  CAS  Google Scholar 

  175. Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol. 1999;19:314–16.

    Article  PubMed  CAS  Google Scholar 

  176. Mantovani G, Maccio A, Madeddu C, et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status. Int J Cancer. 2002;98:84–91.

    Article  PubMed  CAS  Google Scholar 

  177. Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: Effects on cognitive processes. Neuroimmunomodulation. 2003;10:319–27.

    Article  CAS  Google Scholar 

  178. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004;25:94–102.

    Article  PubMed  CAS  Google Scholar 

  179. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–93.

    Article  PubMed  CAS  Google Scholar 

  180. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11:279–92.

    Article  PubMed  CAS  Google Scholar 

  181. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919–25.

    Article  PubMed  Google Scholar 

  182. Valentine AD, Meyers CA. Neurobehavioral effects of interferon therapy. Curr Psychiatry Rep. 2005;7:391–5.

    Article  PubMed  Google Scholar 

  183. Scheibel RS, Valentine AD, O'Brien S, et al. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 2004;16:185–91.

    Article  PubMed  CAS  Google Scholar 

  184. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999;461:75–81.

    Article  PubMed  CAS  Google Scholar 

  185. Collado-Hidalgo A, Bower JE, Ganz PA, et al. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006;12:2759–66.

    Article  PubMed  CAS  Google Scholar 

  186. Vardy J, Booth C, Pond GR, Galica J, Zhang H, Dhillon H, Clarke SJ, Tannock IF. Cytokine levels in patients with colorectal cancer and breast cancer and their relationship to fatigue and cognitive function. American Society of Clinical Oncology. Chicago, 2007

    Google Scholar 

  187. Liberman JN, Stewart WF, Wesnes K, et al. Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. Neurology. 2002;58:1038–44.

    PubMed  CAS  Google Scholar 

  188. Tardiff BE, Newman MF, Saunders AM, et al. Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Ann Thorac Surg. 1997;64:715–20.

    Article  PubMed  CAS  Google Scholar 

  189. Roses AD, Saunders AM. ApoE, Alzheimer's disease, and recovery from brain stress. Ann N Y Acad Sci. 1997; 826:200–12.

    Article  PubMed  CAS  Google Scholar 

  190. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.

    Article  PubMed  Google Scholar 

  191. Jamroziak K, Robak T. Pharmacogenomics of MDR1/ABCB1 gene: The influence on risk and clinical outcome of haematological malignancies. Hematology. 2004;9:91–105.

    Article  PubMed  CAS  Google Scholar 

  192. Kreb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4–33.

    Article  CAS  Google Scholar 

  193. Blasiak J, Arabski M, Krupa R, et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res. 2004;554:139–48.

    Article  PubMed  CAS  Google Scholar 

  194. Morley KI, Montgomery GW. The genetics of cognitive processes: Candidate genes in humans and animals. Behav Genet. 2001;31:511–31.

    Article  PubMed  CAS  Google Scholar 

  195. Savitz J, Solms M, Ramesar R. The molecular genetics of cognition: Dopamine, COMT and BDNF. Genes Brain Behav. 2006;5:311–28.

    Article  PubMed  CAS  Google Scholar 

  196. Schroder CP, Wisman GB, de Jong S, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer. 2001;84:1348–53.

    Article  PubMed  CAS  Google Scholar 

  197. Vasa-Nicotera M, Brouilette S, Mangino M, et al. Mapping of a major locus that determines telomere length in humans. Am J Hum Genet. 2005;76:147–51.

    Article  PubMed  CAS  Google Scholar 

  198. Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001;19:1802–8.

    PubMed  CAS  Google Scholar 

  199. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16:2522–7.

    PubMed  CAS  Google Scholar 

  200. Mar Fan HG, Chemerenysky I, Xu W, Clemons M, Tannock IF. A randomised, placebo-controlled double-blind trial of the effects of d-methylphenidate therapy on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy, Canadian Breast Cancer Research Alliance Reasons for Hope 4th Scientific Conference. Montreal, 2006 Abstract M156.

    Google Scholar 

  201. Lower E, Fleishman S, Cooper A, et al. A phase III, randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and “chemobrain” in adult cancer patients. J Clin Oncol (Meeting Abstracts). 23:8000.

    Google Scholar 

  202. Le Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dement Geriatr Cogn Disord. 2000;11:230–7.

    Article  PubMed  CAS  Google Scholar 

  203. Le Bars PL. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles. Pharmacopsychiatry. 2003;36(Suppl 1):S50–5.

    PubMed  CAS  Google Scholar 

  204. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992;34:352–8.

    PubMed  CAS  Google Scholar 

  205. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev:CD003120. 2002.

    Google Scholar 

  206. Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology (Berl). 2000;152:353–61.

    Article  CAS  Google Scholar 

  207. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl). 2000;151:416–23.

    Article  CAS  Google Scholar 

  208. Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharmacol Res. 1984;4:89–93

    PubMed  CAS  Google Scholar 

  209. Birks J. Does donepezil improve well-being for dementia due to Alzheimer's disease? Neuroepidemiology. 2005;24:168–9.

    Article  PubMed  Google Scholar 

  210. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev:CD005593. 2006.

    Google Scholar 

  211. Christodoulou C, Melville P, Scherl WF, et al. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci. 2006;245:127–36.

    Article  PubMed  CAS  Google Scholar 

  212. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63:1579–85.

    PubMed  CAS  Google Scholar 

  213. Birks J, Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 3:CD006104. 2006.

    Google Scholar 

  214. Eslinger PJ. Neuropsychological Interventions: Clinical Research and Practice. New York: Guilford Press; 2002.

    Google Scholar 

  215. Sohlberg MM, Mateer CA. Introduction to Cognitive Rehabilitation: Theory and Practice. New York: Guilford Press; 1989.

    Google Scholar 

  216. Sohlberg MM, Mateer CA. Cognitive Rehabilitation: An Integrative Neuropsychological Approach. New York: Guilford Press; 2001

    Google Scholar 

  217. Cicerone KD, Dahlberg C, Kalmar K, et al. Evidence-based cognitive rehabilitation: Recommendations for clinical practice. Arch Phys Med Rehabil. 2000;81:1596–615.

    Article  PubMed  CAS  Google Scholar 

  218. Carney N, Chesnut RM, Maynard H, et al. Effect of cognitive rehabilitation on outcomes for persons with traumatic brain injury: A systematic review. J Head Trauma Rehabil. 1999;14:277–307.

    Article  PubMed  CAS  Google Scholar 

  219. Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury. JAMA. 1999;282:974–83.

    Google Scholar 

  220. Mateer CA, Sira CS, O'Connell ME. Putting Humpty Dumpty together again: The importance of integrating cognitive and emotional interventions. J Head Trauma Rehabil. 2005;20:62–75.

    Article  PubMed  Google Scholar 

  221. Sohlberg MM, McLaughlin KA, Pavese A, et al. Evaluation of attention process training and brain injury education in persons with acquired brain injury. J Clin Exp Neuropsychol. 2000;22:656–76.

    Article  PubMed  CAS  Google Scholar 

  222. Cimprich B. Age and extent of surgery affect attention in women treated for breast cancer. Res Nurs Health. 1998;21:229–38.

    Article  PubMed  CAS  Google Scholar 

  223. Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res. 2001;50:86–94.

    Article  PubMed  CAS  Google Scholar 

  224. Gottschalk LA, Holcombe RF, Jackson D, et al. The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol. 2003;25:117–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sydney Cancer Centre, Concord Repatriation General Hospital, Department of Medical Oncology, The University of Sydney, Cancer Institute NSW, Sydney, Concord, Australia

    Janette Vardy

Authors
  1. Janette Vardy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Janette Vardy .

Editor information

Editors and Affiliations

  1. Inselspital, Univ. Bern, Bern, 3010, Switzerland

    Monica Castiglione

  2. Inst. Jules Bordet, Universite Libre Bruxelles, Bd. de Waterloo 125, Bruxelles, 1000, Belgium

    Martine J. Piccart

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Vardy, J. (2009). Cognitive Function in Breast Cancer Survivors. In: Castiglione, M., Piccart, M. (eds) Adjuvant Therapy for Breast Cancer. Cancer Treatment and Research, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-75115-3_24

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-75115-3_24

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-75114-6

  • Online ISBN: 978-0-387-75115-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation